BACKGROUND AND AIMS Questions related to the safety and long-term efficacy of endoscopic sleeve gastroplasty (ESG) are not yet answered. Here we report weight loss, morbidity, revisions, and comorbidity resolution during the first 18 months after primary ESG. METHODS This is a consecutive case series from a prospective observational study executed in a specialized center with a standardized pathway for multimodal management of obesity. RESULTS The 1000 patients in this study had a baseline body mass index of 33.3 ± 4.5 kg/m2 and age of 34.4 ± 9.5 years. Eight hundred ninety-seven patients (89.7%) were women. Mean percentage of total weight loss at 6, 12, and 18 months was 13.7% ± 6.8% (n = 369; follow-up rate = 423; 87.2%), 15.0% ± 7.7% (n = 216; follow-up rate = 232; 93.1%), and 14.8% ± 8.5% (n = 54; follow-up rate = 63; 85.7%), respectively. Lost to follow-up at the 12- and 18-month visits were 6.9% and 14.3%, respectively. Thirteen of 17 cases of diabetes, all 28 cases of hypertension, and 18 of 32 cases of dyslipidemia were in complete remission by the third month. With regard to postoperative complaints, 924 patients (92.4%) complained of nausea or abdominal pain that was controlled with medications during the first week after ESG. Twenty-four patients were readmitted: 8 for severe abdominal pain, of whom 3 had ESG reversal; 7 for postprocedure bleeding, 2 of whom received 2 units of packed red blood cells each; 4 for perigastric collection with pleural effusion, 3 of whom underwent percutaneous drainage; and 5 for postprocedure fever with no sequelae. Eight patients were revised to sleeve gastrectomy, and 5 had redo-ESG. No patient required an emergency intervention, and there were no mortalities. CONCLUSIONS ESG appears to be well tolerated, safe, and effective. Significant weight loss occurs during the first 18 months without mortality or significant morbidity. Some patients require revision or reversal during the first year.

中文翻译：

---

连续1000例患者的内镜下袖胃成形术的近期结果。

背景和目的尚未解决与内窥镜套管胃成形术（ESG）的安全性和长期疗效有关的问题。在这里，我们报告了原发ESG后头18个月的体重减轻，发病率，修正和合并症的缓解情况。方法这是来自前瞻性观察研究的连续病例系列，前瞻性观察研究是在专门中心进行的，采用标准化途径进行肥胖症的多模式管理。结果本研究的1000名患者的基线体重指数为33.3±4.5 kg / m2，年龄为34.4±9.5岁。女性为八百九十七名患者（89.7％）。在6、12和18个月时，总减肥的平均百分比为13.7％±6.8％（n = 369；随访率= 423; 87.2％），15.0％±7.7％（n = 216;随访率） = 232; 93.1％）和14.8％±8.5％（n = 54;随访率= 63; 85.7％）。在随访的12个月和18个月中，随访失败率分别为6.9％和14.3％。到第三个月，17例糖尿病患者中的13例，全部28例高血压和32例血脂异常中的18例完全缓解。关于术后主诉，有924例患者（92.4％）抱怨有恶心或腹痛，这是在ESG术后的第一周内用药物控制的。再次入院的患者有24例：严重腹痛8例，其中ESG逆转3例；术后出血为7例，其中2例分别接受了2个装满红细胞的单位；4例因腹腔积液伴有胸腔积液，其中3例经皮引流；5例无后遗症。8例患者接受了袖式胃切除术修订，其中5例进行了重做ESG。没有患者需要紧急干预，没有死亡。结论ESG似乎具有良好的耐受性，安全性和有效性。在开始的18个月内体重明显减轻，没有死亡或高发病率。一些患者在第一年需要翻修或逆转。